Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 17/20 | 0.58 |
| ▸ | PDE5A | O76074 | 4/20 | 0.58 |
| ▸ | PDE2A | O00408 | 2/20 | 0.58 |
| ▸ | PDE8A | O60658 | 2/20 | 0.58 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.58 |
| ▸ | PDE11A | Q9HCR9 | 2/20 | 0.58 |
| ▸ | PDE7B | Q9NP56 | 2/20 | 0.58 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.58 |
| ▸ | PDE9A | O76083 | 1/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12280991 | 0.87 | PDE4A (0.51) | PDE4APDE5A | |
| SCHEMBL2362468 | 0.86 | PDE4A (0.63) | PDE4A | |
| SCHEMBL2361338 | 0.82 | PDE4A (0.56) | PDE4APDE5APDE2APDE8APDE3B | |
| SCHEMBL2361465 | 0.82 | PDE4A (0.60) | PDE4APDE5APDE2APDE8APDE3B | |
| SCHEMBL2362351 | 0.81 | PDE5A (0.49) | PDE4APDE5APDE4BPDE4CPDE4D | |
| SCHEMBL2412384 | 0.79 | PDE4A (0.58) | PDE4APDE5APDE2APDE8APDE3B | |
| SCHEMBL2361395 | 0.79 | PDE4A (0.68) | PDE4APDE5APDE2APDE8APDE3B | |
| SCHEMBL2417050 | 0.79 | PDE4A (0.73) | PDE4APDE5APDE2APDE8APDE3B | |
| SCHEMBL12281231 | 0.77 | PDE4A (0.71) | PDE4APDE5APDE2APDE8APDE3B | |
| SCHEMBL8245508 | 0.73 | PDE4A (0.83) | PDE4APDE5APDE2APDE8APDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358204-B1 | 4,5,7,8-tetrahydro-4-oxo-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors. | INTRA CELLULAR THERAPIES INC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2358204-B1 | 4,5,7,8-tetrahydro-4-oxo-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors. | INTRA CELLULAR THERAPIES INC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20150072965-A1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150072965-A1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150072965-A1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2015-03-12 | — | — | US | disclosed |
| US-20140148421-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148421-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148421-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8664207-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664207-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664207-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20110237561-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2011-09-29 | — | — | US | disclosed |
| US-20110237561-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2011-09-29 | — | — | US | disclosed |
| US-20110237561-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2011-09-29 | — | — | US | disclosed |
| EP-2358204-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010065148-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065148-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148421-A1 | ORGANIC COMPOUNDS | TPMT, TYMS, THPO | PDE4A 989/4885PDE5A 1584/4885PDE2A 1835/4885 |
| US-20150072965-A1 | ORGANIC COMPOUNDS | TPMT, TYMS, THPO | PDE4A 989/4885PDE5A 1584/4885PDE2A 1835/4885 |
| US-20110237561-A1 | ORGANIC COMPOUNDS | TPMT, TYMS, THPO | PDE4A 989/4885PDE5A 1584/4885PDE2A 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.